Cargando…
671. Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)
BACKGROUND: MRSA infections, especially involving the endovascular system (e.g., IE), are associated with unacceptably high morbidity and mortality rates. The use of bacteriophage-derived lysin, which acts as direct lytic agents, represents a novel adjunctive approach against virulent Gram-positive...
Autores principales: | Xiong, Yan, Abdelhady, Wessam, Li, Liang, Schuch, Raymond, Cassino, Cara, Lehoux, Dario, Bayer, Arnold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811205/ http://dx.doi.org/10.1093/ofid/ofz360.739 |
Ejemplares similares
-
Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
por: Karau, Melissa, et al.
Publicado: (2022) -
712. Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires
por: Karau, Melissa J, et al.
Publicado: (2019) -
1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models
por: Ghahramani, Parviz, et al.
Publicado: (2019) -
711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)
por: Anastasiou, Diane, et al.
Publicado: (2019) -
1342. Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates
por: Anastasiou, Diane, et al.
Publicado: (2018)